Clinical trials: EGFR Mutant Advanced Non-small Cell Lung Cancer
Solid Tumors
MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Participants with Select Advanced Solid Tumors
- Trial name
- NCT02503774
- Testing
- Oleclumab, Durvalumab
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 192 people
- Sponsor
- MedImmune LLC
Non Small Cell Lung Cancer
Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)
In this study, we hypothesized that immune engagement by amivantamab will enhance antitumor efficacy by modulating the immune microenvironment in combination with lazertinib in patients with untreated EGFR-mutant NSCLC or with…
- Trial name
- INSTAR (NCT07507188)
- Testing
- Amivantamab SC + Lazertinib PO, Amivantamab SC + Chemotherapy (Carboplatin IV & Pemetrexed IV)
- Volunteers
- 80 people
- Sponsor
- Yonsei University
EGFR Mutant Advanced Non Small Cell Lung Cancer
Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.
The primary purpose of this trial is to evaluate the efficacy and tolerability of durvalumab and tremelimumab with platinum-pemetrexed in patients with metastatic NSCLC (T790+ve or T790M-ve) following progression on EGFR Tyrosine…
- Trial name
- ILLUMINATE (NCT03994393)
- Testing
- Tremelimumab, Durvalumab
- Where
- 16 sites in Australia, Taiwan
- Volunteers
- 100 people
- Sponsor
- University of Sydney
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
This phase II trial studies how well cabozantinib-s-malate and erlotinib hydrochloride works in treating patients with previously treated metastatic non-small cell lung cancer.
- Trial name
- NCT01866410
- Testing
- Cabozantinib S-malate, Erlotinib Hydrochloride, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Non-Squamous Non-Small Cell Lung Cancer
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
The anti-tumor activity of anti-PD-1 therapy and VEGF inhibitor in TKI-resistant EGFR-mutated non-squamous NSCLC Chinese patients will be investigated in this clinical trial.
- Trial name
- NCT03802240
- Testing
- Sintilimab, IBI305, Pemetrexed
- Where
- China
- Volunteers
- 492 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Non-Small Cell Lung Cancer
Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
This research study is studying a combination of two drugs as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation.
- Trial name
- NCT03122717
- Testing
- Gefitinib, Osimertinib
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Dana-Farber Cancer Institute
Non-small Cell Lung Cancer
A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC
This clinical research study is being carried out in two parts, Phase 1 and Phase 2. The primary purpose of the Phase 1 portion of the study is to observe the safety of the combination of rociletinib and MPDL3280A in EGFR-mutant…
- Trial name
- NCT02630186
- Testing
- Rociletinib, MPDL3280A
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Clovis Oncology, Inc.
Metastatic Lung Non-Small Cell Carcinoma, EGFR T790M
Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer
It is to evaluate the safety and effectiveness of a lasertinib(LECLAZA) single drug in a actual medical environment for patients 1. Primary Purpose: Progression-free survival (PFS) 2.
- Trial name
- NCT05377788
- Testing
- Lazertinib
- Where
- South Korea
- Volunteers
- 900 people
- Sponsor
- Samsung Medical Center
Carcinoma, Non-Small-Cell Lung, EGFR Mutant Advanced Non-Small Cell Lung Cancer
A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients
This is a Phase 1/2, open-label study designed to investigate the safety, tolerability, PK, and anti-tumor activity of the study treatment in the treatment of patients with EGFR mutant NSCLC, who progressed following prior…
- Trial name
- NCT06186076
- Testing
- TRX-221
- Where
- 6 sites in South Korea
- Volunteers
- 19 people
- Sponsor
- Therapex Co., Ltd
Locally Advanced or Metastatic Non Small Cell Lung Cancer
Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients
Rociletinib is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while sparing wild-type (WT) EGFR.
- Trial name
- NCT01526928
- Testing
- Rociletinib
- Where
- 49 sites in United States, Australia and 2 more
- Volunteers
- 612 people
- Sponsor
- Clovis Oncology, Inc.
Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer
A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy
The "PACIFIC" trial confirmed that the consolidation therapy with durvalumab in patients with stage III, locally advanced, unresectable NSCLC that had not progressed after definitive platinum-based chemoradiation therapy improved…
- Conditions
- Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
- Trial name
- PLATINUM (NCT05338619)
- Testing
- Lazertinib
- Where
- 13 sites in South Korea
- Volunteers
- 77 people
- Sponsor
- Sung Yong Lee
Non-Small Cell Lung Cancer
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer
This research study is studying a combination of two drugs as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation.
- Trial name
- NCT05007938
- Testing
- Icotinib, Befotertinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
This is a phase II, open-label, single-arm, single-center clinical study to evaluate the preliminary efficacy of sunvozertinib in combination with anlotinib in patients with EGFR-sensitive mutations and co-mutations in locally…
- Trial name
- WUKONG-32-RW (NCT06355609)
- Testing
- sunvozertinib in combination with Anlotinib
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hunan Province Tumor Hospital
EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China
This is a single-center, single-dose, open-label, Phase I study to evaluate the mass balance, biotransformation, pharmacokinetic characteristics, excretion pathways, and safety of a single oral 200 mg/5 µCi dose of…
- Trial name
- NCT07620951
- Testing
- [14C]Zorifertinib Oral Formulation
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to…
- Trial name
- NCT05642572
- Testing
- Biospecimen Collection, Capmatinib, Computed Tomography
- Where
- 454 sites in United States
- Volunteers
- 66 people
- Sponsor
- SWOG Cancer Research Network
Non Small Cell Lung Cancer, Circulating Tumor Cell
CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC
clinical trial The goal of this clinical trial is to learn whether the treatment of advanced non-small cell lung cancer with EGFR-TKIs, when combined with bevacizumab in the presence of positive circulating tumor cells in the…
- Conditions
- Non Small Cell Lung Cancer, Circulating Tumor Cell, EGF-R Positive Non-Small Cell Lung Cancer
- Trial name
- NCT06557096
- Testing
- Osimertinib 80 MG, Bevacizumab
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
EGFR, NSCLC (Non-small Cell Lung Cancer)
Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC
The subjects of this study are patients with unresectable stage III non-small cell lung cancer (NSCLC) who have EGFR mutations.
- Conditions
- EGFR, NSCLC (Non-small Cell Lung Cancer), Locally Advanced Non-Small Cell Lung Cancer, Radiotherapy
- Trial name
- NCT07742332
- Testing
- Fumetinib combined platinum-based double chemotherapy, Concurrent Radiochemotherapy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Peng Zhang
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
This phase Ib trial evaluates the best dose and side effects of MRX-2843 when given in combination with osimertinib in treating patients with EGFR gene mutant non-small cell lung cancer that has spread to other places in the body…
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT04762199
- Testing
- Flt3/MerTK Inhibitor MRX-2843, Osimertinib
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Emory University
Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung), Drug-Related Side Effects and Adverse Reactions (MeSH Term)
Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer
This study investigated the incidence of cardiac dysfunction in patients with advanced or recurrent epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR- tyrosine kinase inhibitors.
- Conditions
- Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung), Drug-Related Side Effects and Adverse Reactions (MeSH Term), Egfr Tyrosine Kinase Inhibitor, Cardiotoxicity
- Trial name
- NCT07267247
- Testing
- EGFR-TKI, EGFR tyrosine kinase inhibitor
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Taichung Veterans General Hospital
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change…
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT04181060
- Testing
- Bevacizumab, Biospecimen Collection, Computed Tomography
- Where
- 603 sites in United States
- Volunteers
- 300 people
- Sponsor
- National Cancer Institute (NCI)